Intervention Review

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

  1. Robert Caslake1,
  2. Angus Macleod2,
  3. Natalie Ives3,
  4. Rebecca Stowe3,
  5. Carl Counsell4,*

Editorial Group: Cochrane Movement Disorders Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 19 FEB 2009

DOI: 10.1002/14651858.CD006661.pub2


How to Cite

Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD006661. DOI: 10.1002/14651858.CD006661.pub2.

Author Information

  1. 1

    University of Aberdeen, Medecine & Therapeutics, Aberdeen, UK

  2. 2

    University of Aberdeen, Medicine and Therapeutics, Aberdeen, UK

  3. 3

    Robert Aitken Institute, University of Birmingham, Birmingham Clinical Trials Unit, School of Cancer Sciences, Birmingham, UK

  4. 4

    University of Aberdeen, Division of Applied Health Sciences, Aberdeen, UK

*Carl Counsell, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. carl.counsell@abdn.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2009

SEARCH

  1. Current Version

    Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

    Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Article first published online: 7 OCT 2009 | DOI: 10.1002/14651858.CD006661.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

    Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Article first published online: 18 JUL 2007 | DOI: 10.1002/14651858.CD006661